This presentation reviews the importance of early diagnosis for enhancing outcomes in patients with type 2 Diabetes and the implementation of evidence-based strategies for managing these patients. Also discussed are newer therapies in management of type 2 Diabetes, with a focus on underlying pathophysiology, and the role of a chronic care model in optimizing Diabetes care.
This webcast was recorded live and is being used with the permission of the presenter.
- Recognize the importance of early diagnosis for enhancing outcomes in type 2 diabetes
- Implement evidence-based strategies for type 2 diabetes management
- Define the role of newer therapies in the pathophysiology and management of type 2 diabetes
- Discuss the role of the chronic care model in optimizing diabetes care
AMA PRA Category 1 Credit(s)TM
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Mark Stolar, MD
Associate Professor of Clinical Medicine at Northwestern University Medical School,
Mark Stolar, MD, is on the speaker's bureaus for Boehringer-Ingelheim/Lilly and Takeda. He is also on the advisory board for Takeda and participates in an educational program with Abbott Diagnostic.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Harvey Parker, PhD, Activity Planning Committee, has no relationships to disclose.
Robert S. Busch, MD, FACE, Activity Planning Committee, is on the speaker's bureaus for Merck, Takeda, Amgen, Novo Nordisk, and Abbott. He is also on the advisory board for Amylin and is the principal investigator for Lilly.
Patrick Boyle, MD, Activity Planning Committee, is a speaker for Amylin, Eli Lilly, Takeda, and Boehringer-Ingelheim.
Frank Lavernia, MD, Activity Planning Committee, is a speaker for Abbott.
None of the planners/peer reviewers have any relevant financial relationships to disclose.
National Association for Continuing Education
Boehringer-Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through a collaboration with Eli Lilly and Company, provided commercial support for this enduring activity.
To obtain credit, a score of 60% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test, and received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.